GPT and gastroesophageal reflux disease: Nevertheless, a subsequent phase 2b study has found that lesogaberan 240 mg does not have a clinically important effect on GERD symptoms in partial responders to PPI treatment[22] which, in combination with some potential safety signals (reversible elevated alanine transaminase levels >5 times the upper limit of normal in 6 patients), led to the discontinuation of the development of lesogaberan in 2012.